Clinical data from published peer-reviewed studies.
67% IPSS improvement, 103% Qmax increase, ~95.6% ejaculation preserved, 4.29% overall complication rate — validated across 4 PubMed-indexed studies and multiple Chinese core-journal papers covering over 3,000 patients.
Data sources: All data on this page are from published peer-reviewed literature and expert consensus documents. Full references at the bottom of the page. See also our technology explainer for how TUCBDP achieves these outcomes.
IPSS Improvement
From 20.2 to 6.6. Huang 2016 (N=565), median FU >3 yr.
Complication Rate
TUCBDP vs. 12.86% TURP (P=0.042). Zhang 2022.
Ejaculation Preserved
Retrograde ejaculation 4.45%. Gao et al. (N=265).
Key efficacy endpoints
| Endpoint | Baseline | Post-treatment | Improvement | Source (N) |
|---|---|---|---|---|
| IPSS | 20.2 ± 4.4 | 6.6 ± 1.1 | 67% ↓ | Huang 2016 (565) |
| Qmax (mL/s) | 8.91 ± 3.13 | 18.11 | 103% ↑ | Zhou 2022 (2,050) |
| PVR (mL) | 76 ± 8 | 20 ± 8.5 | 74% ↓ | Huang 2016 (565) |
| QoL Score | 4.6 ± 0.2 | 1.4 ± 0.3 | 70% ↓ | Huang 2016 (565) |
Surgery efficiency
| Parameter | Value | Source |
|---|---|---|
| Procedure time | 10–25 min | Huang 2016 (~10–15 min); Zhang 2022 (18.6±3.2 min); Wang 2020 (25.3±8.6 min) |
| Catheter indwelling | 2.5–3.3 days | Zhang 2022 (2.5±0.5d); Wang 2020 (78.9±16.5h) |
| Hospital stay | 1.9–2.9 days | Wang 2020 (1.9±0.9d); Zhang 2022 (2.9±0.7d) |
| Intraoperative blood loss | 13.2 ± 4.0 mL | Zhang 2022 (vs. TURP 66.5±18.4, P=0.000) |
| Bladder irrigation time | 6.3 ± 2.0 h | Zhang 2022 (vs. TURP 45.1±13.8, P=0.000) |
Complications — two definitions, two results
Complication rates vary by definition. Zhang 2022 uses a narrow surgical definition; Gao et al. reports a broader set of all post-procedural events. See full MIST comparison for context on how Nexusuro compares to other modalities.
Zhang 2022 — Prospective controlled (N=140)
| Event | TUCBDP | TURP |
|---|---|---|
| Secondary bleeding | 1 | 4 |
| Urinary retention | 0 | 1 |
| Bladder neck spasm | 1 | 2 |
| Urinary incontinence | 1 | 3 |
| Total complication rate | 4.29% | 12.86% |
P=0.042. Zhang D et al. World J Clin Cases. 2022.
Gao et al. — Single-center (N=265)
| Event | Rate |
|---|---|
| Transient incontinence | 10.56% |
| Urinary retention | 3.01% |
| Retrograde ejaculation | 4.45% |
| Overall (incl. minor) | ~20% |
Gao WX et al. Hubei Provincial Hospital of TCM. Literature compilation p.70.
Sexual function
| Measure | Baseline | Post-treatment | Result | Source (N) |
|---|---|---|---|---|
| Ejaculation preserved | — | 95.6% | Retrograde ejaculation 4.45% | Gao et al. (265) |
| Erectile function (IIEF-5) | 20.96 ± 2.03 | 21.42 | Not affected (p≤0.001) | Zhou 2022 (2,050) |
| MSHQ-EjD-SF | 10.47 ± 1.72 | improved | p≤0.001 | Zhou 2022 (2,050) |
| IIEF-5 (supplementary) | — | 22.71 | Good postoperative function | Wang LM et al. (265) |
Long-term durability
Huang 2016 — N=565, median follow-up >3 years (38–99 months)
| Metric | Value |
|---|---|
| IPSS at last follow-up | 6.6 ± 1.1 (maintained) |
| Qmax at last follow-up | 12.8 ± 2.2 mL/s (maintained) |
| Reoperation rate | 0.35% (2/565) |
Additional finding from Wang 2020: BNC at 1 year — TUSP 2.0% vs TURP 15.7% (P=0.031).
Published references
PubMed-indexed studies (4)
- Huang 2016 — N=565, 38–99mo FU. Medicine. PMID: 27749528
- Wang 2020 — N=101, RCT. Ann Transl Med. PMC7475497
- Zhou 2022 — N=2,050, 11-city multicenter. Biomed Res Int. PMC9203188
- Zhang 2022 — N=140, RCT. World J Clin Cases. PMC9297432
Chinese core journals + consensus (5+)
- Gao WX et al. — N=265. Hubei Prov. Hosp. of TCM.
- Wang LM et al. — N=265. North China Univ. of Sci. & Tech.
- Zhang YF et al. — N=70. Anhui Medical University.
- Zhou GY et al. — N=60. Lanxi Hospital of TCM.
- Chinese Medical Association — Expert Consensus (2022)
Review the full clinical data package
Schedule a presentation with our medical affairs team for detailed study walkthroughs and the complete literature compilation.
Clinical data on this page are sourced from published peer-reviewed literature and expert consensus documents. Individual results vary. This page does not constitute medical advice. Manufactured in partnership with Hangzhou Hongyuan Medical Co., Ltd., a company holding NMPA registration and ISO 13485 certification.